Clopidogrel Bisulphate API&Pellet

Clopidogrel Bisulphate Manufacturers in India - API&Pellet 1

Product Description:

  • Therapeutic Category : Antithrombotic / Anticoagulant
  • CAS Number : 120202-66-6
  • Molecular Formula : C16H18ClNO6S2
  • Molecular Weight: 419.9 g/mol
  • Mesh Size : As per Customer Requirement
  • Form : Tablet,Capsule
  • Metrochem Development Status : Commercial

Metrochem API one of the major Clopidogrel Bisulphate API and Pellet Manufacturers in India. We are emerging as India’s leading manufactures of APIs, Intermediates, pellets delivering quality pharmaceutical products. Despite a high customer retention rate, we are well reputed for the best products in the industry.

Mechanism of action

Clopidogrel Bisulphate is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. A variety of drugs that inhibit platelet function have been shown to decrease morbid events in people with established cardiovascular atherosclerotic disease as evidenced by stroke or transient ischemic attacks, myocardial infarction, unstable angina or the need for vascular bypass or angioplasty. This indicates that platelets participate in the initiation and/or evolution of these events and that inhibiting platelet function can reduce the event rate.

Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.

Indication:

Clopidogrel Bisulphate is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. -For patients with ST-segment elevation acute myocardial infarction, Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, reinfarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty.

Metrochem API Expertise:

Metrochem API Pvt Ltd is a leading manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) through our manufacturing sites in Hyderabad and Vizag. Our API facilities have been inspected and approved by several global regulatory bodies including the US FDA, Japan PMDA, KFDA, and meet the cGMP compliance standards. Adapting quickly to the ever-evolving demands, we have emerged as one of the fastest growing organization in the pharmaceutical industry across the India. To cater our customer high volume requirements, we have dedicated each of our 6 manufacturing facilities to our 3 core product groups – APIs, Pelletization& Intermediates – reinforced by a well equipped, centralized Research & Development laboratory.

We have been successfully supplying APIs all over the globe for more than 15 years. Total reactor volume exceeds 1200 KL which includes pilot and multi-purpose units. We are capable of executing extensive API requirements for our customers. Metrochem API Pvt Ltd has an experienced team of highly skilled chemists, experienced regulatory professionals and supply chain experts, who are ready to handle your API manufacturing requirements with expert care. We also offer Contract Manufacturing, Contract Research, and Custom Synthesis services. We have a stand-alone R&D center located in Hyderabad with State-of-the-art analytical facilities and over 90 scientists. We have extensively worked on and delivered new products across a wide variety of therapeutic segments and as a company, we have built strong expertise in new product development.

Close Menu